Bharat Biotech submits Covaxins Phase III trial data to DCGI.
Hyderabad-based COVID vaccine manufacturing company Bharat Biotech submitted data from Covaxin’s phase III clinical trials to the Controller General of Drugs of India (DCGI) over the weekend, according to government sources.
“We have received the data from the phase III trials,” confirmed a senior government official.
Covaxin from Bharat Biotech is one of three vaccines currently in use in India. The phase III data of your vaccine has been questioned multiple times and that is what makes the data crucial in determining the efficacy of the vaccine.
The company has developed the vaccine in partnership with the Indian Council for Medical Research (ICMR).
At a press conference a few days ago by the Union Health Ministry, Dr. VK Paul, who is a member (Health) Niti Aayog and also the head of the country’s COVID working group, said that the company would send the data within seven to eight days.
She is a freelance blogger, writer, and speaker, and writes for various entertainment magazines.